Masaki Nakamura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4517388/publications.pdf

Version: 2024-02-01

		1040056	1125743	
29	250	9	13	
papers	citations	h-index	g-index	
20	20	20	245	
29	29	29	345	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Impacts of the STINGâ€IFNAR1â€6TAT1â€IRF1 pathway on the cellular immune reaction induced by fractionated irradiation. Cancer Science, 2022, 113, 1352-1361.	3.9	7
2	Comprehensive screening for drugs that modify radiation-induced immune responses. British Journal of Cancer, 2022, , .	6.4	2
3	Identification of the mutation signature of the cancer genome caused by irradiation. Radiotherapy and Oncology, 2021, 155, 10-16.	0.6	6
4	Liquid Biopsy Cell-free DNA Biomarkers in Patients With Oligometastatic Colorectal Cancer Treated by Ablative Radiotherapy. Anticancer Research, 2021, 41, 829-834.	1.1	9
5	Comparison of a Hybrid IMRT/VMAT technique with non-coplanar VMAT and non-coplanar IMRT for unresectable olfactory neuroblastoma using the RayStation treatment planning systemâ€"EUD, NTCP and planning study. Journal of Radiation Research, 2021, 62, 540-548.	1.6	4
6	Long-term clinical outcomes of patients diagnosed with pT1a-muscularis mucosae with lymphovascular invasion or pT1b after endoscopic resection for cT1N0M0 esophageal squamous cell carcinoma. Esophagus, 2021, , 1.	1.9	3
7	Radiation pneumonitis after palliative radiotherapy in cancer patients with interstitial lung disease. Radiotherapy and Oncology, 2021, 161, 47-54.	0.6	8
8	Comparative analysis of the immune responses in cancer cells irradiated with X-ray, proton and carbon-ion beams. Biochemical and Biophysical Research Communications, 2021, 585, 55-60.	2.1	11
9	Could excision repair crossâ€complementing groupâ€1 mRNA expression from peripheral blood lymphocytes predict locoregional failure with cisplatin chemoradiation for locally advanced laryngeal cancer?. Asia-Pacific Journal of Clinical Oncology, 2020, 16, e19-e26.	1.1	1
10	Impact of Proton Beam Irradiation of an Anatomic Subsegment of the Liver for Hepatocellular Carcinoma. Practical Radiation Oncology, 2020, 10, e264-e271.	2.1	0
11	Dose–Volume and Radiobiological Model-Based Comparative Evaluation of the Gastrointestinal Toxicity Risk of Photon and Proton Irradiation Plans in Localized Pancreatic Cancer Without Distant Metastasis. Frontiers in Oncology, 2020, 10, 517061.	2.8	5
12	Palliative Radiation Therapy for Macroscopic Hematuria Caused by Urothelial Cancer. Palliative Medicine Reports, 2020, 1, 201-207.	0.9	2
13	Differences in failure patterns according to the EGFR mutation status after proton beam therapy for early stage non-small cell lung cancer. Radiotherapy and Oncology, 2020, 149, 14-17.	0.6	3
14	Radiobiological model-based approach to determine the potential of dose-escalated robust intensity-modulated proton radiotherapy in reducing gastrointestinal toxicity in the treatment of locally advanced unresectable pancreatic cancer of the head. Radiation Oncology, 2020, 15, 157.	2.7	2
15	Prospective evaluation of XRCCâ€1 Arg194Trp polymorphism as bioâ€predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatinâ€based chemoradiation. Head and Neck, 2020, 42, 1045-1056.	2.0	7
16	PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation. Journal of Radiation Research, 2020, 61, 177-186.	1.6	14
17	TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma. BMC Cancer, 2020, 20, 336.	2.6	27
18	Efficacy and safety of accelerated fractionated radiotherapy without elective nodal irradiation for T3NO glottic cancer without vocal cord fixation. Head and Neck, 2020, 42, 1775-1782.	2.0	4

#	Article	IF	CITATIONS
19	Frequency and predictors of detecting early locoregional recurrence/disease progression of oral squamous cell carcinoma with high-risk factors on imaging tests before postoperative adjuvant radiotherapy. International Journal of Clinical Oncology, 2019, 24, 1182-1189.	2.2	5
20	Hypofractionated proton beam therapy for centrally located lung cancer. Journal of Medical Imaging and Radiation Oncology, 2019, 63, 552-556.	1.8	12
21	Pattern of recurrence after CyberKnife stereotactic body radiotherapy for peripheral early non-small cell lung cancer. Journal of Thoracic Disease, 2019, 11, 214-221.	1.4	15
22	Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non–small-cell Lung Cancer. Clinical Lung Cancer, 2019, 20, e256-e264.	2.6	22
23	Clinical log data analysis for assessing the accuracy of the CyberKnife fiducial-free lung tumor tracking system. Practical Radiation Oncology, 2018, 8, e63-e70.	2.1	18
24	Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence. Radiation Oncology, 2018, 13, 75.	2.7	10
25	Toxicity of Radiosurgery for Brainstem Metastases. World Neurosurgery, 2018, 119, e757-e764.	1.3	10
26	Late radiological changes after passive scattering proton beam therapy for Stage I lung cancer. Journal of Radiation Research, 2018, 59, 456-461.	1.6	4
27	Impact of prophylactic cranial irradiation on pattern of brain metastases as a first recurrence site for limited-disease small-cell lung cancer. Journal of Radiation Research, 2018, 59, 767-773.	1.6	5
28	Investigation of the efficacy and safety of CyberKnife hypofractionated stereotactic radiotherapy for brainstem metastases using a new evaluation criterion: †symptomatic controlâ€. Journal of Radiation Research, 2017, 58, 834-839.	1.6	9
29	Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer. British Journal of Radiology, 2016, 89, 20160560.	2.2	25